Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA vs DOCA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.
Relief of moderate to moderately severe pain
Adrenocortical insufficiency (Addison's disease),Salt-losing adrenogenital syndrome
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
30-35 minutes; clinical context: short duration necessitates frequent dosing or continuous infusion for sustained effect.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily hepatic metabolism via reduction and conjugation; little is known about specific CYP enzymes.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible (<2%).
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
~70% bound to plasma proteins (primarily albumin).
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Vd: 0.8-1.2 L/kg; indicates extensive tissue distribution with rapid redistribution from effect sites.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Oral: <5% due to extensive first-pass metabolism; IM/SC: 100%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
No specific dose adjustment is recommended for impaired renal function, but monitor for fluid retention and hypertension. Use with caution in patients with significant renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
No specific dose adjustment for hepatic impairment, but use with caution due to potential electrolyte disturbances.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Dose is not well established; use 0.1 to 0.2 mg/kg intramuscularly daily or adjust based on clinical response and serum electrolytes.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Start at the lower end of the dosing range (e.g., 1 to 2 mg IM daily) and monitor closely for fluid overload, hypertension, and electrolyte imbalances due to age-related decreased renal function and comorbidities.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
None
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Fluid overload and edema,Hypokalemia,Hypertension,Cardiac hypertrophy and failure,Increased risk of infection due to immune suppression when used with glucocorticoids
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Hypersensitivity to desoxycorticosterone or any component,Severe renal impairment,Hyperkalemia,Hypocalcemia,Congestive heart failure,Systemic fungal infections
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
No specific food interactions are reported. However, maintain consistent sodium intake; do not restrict salt unless advised. Avoid potassium-rich foods if potassium levels are high. Alcohol may increase the risk of electrolyte disturbances.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: risk of virilization of female fetuses; no adequate human studies; avoid use unless potential benefit outweighs risk.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Excreted in breast milk in low amounts; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., electrolyte disturbances, hypertension). Use caution; consider alternative therapies.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
No specific dose adjustments studied; monitor for increased volume of distribution and clearance; adjust based on clinical response and serum electrolyte levels. Use lowest effective dose.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
DOCA (desoxycorticosterone acetate) is a mineralocorticoid used in adrenal insufficiency. Monitor serum potassium closely due to risk of hypokalemia from excessive mineralocorticoid activity. DOCA requires intramuscular injection; do not administer intravenously. Use in conjunction with glucocorticoids to mimic cortisol's permissive effects on catecholamines. Avoid in patients with hypertension, heart failure, or renal impairment due to sodium and water retention.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
This medication helps maintain salt and water balance in the body.,It is given as an injection into a muscle; do not inject into a vein.,Report signs of excessive fluid retention: swelling in legs, rapid weight gain, shortness of breath.,Monitor for muscle cramps or weakness which may indicate low potassium levels.,Avoid salt substitutes containing potassium without consulting your doctor.,Do not miss appointments for injections as consistent dosing is critical.,Carry medical identification indicating you take corticosteroid replacement therapy.
No interactions on record
"Lidocaine, a sodium channel blocker and Class IB antiarrhythmic, inhibits hepatic CYP3A4, the primary enzyme responsible for the metabolism of quazepam, a benzodiazepine sedative-hypnotic. This inhibition reduces quazepam clearance, leading to elevated serum concentrations and enhanced sedative effects. Clinically, this may result in excessive sedation, respiratory depression, psychomotor impairment, and increased risk of falls, especially in elderly patients or those with hepatic impairment."
"Lidocaine and prilocaine are both amide-type local anesthetics that block voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse propagation. When used together, their systemic absorption can lead to additive cardiovascular and central nervous system toxicity, including arrhythmias, seizures, and methemoglobinemia, particularly with high doses or in patients with predisposing conditions."
"Lidocaine, a class Ib antiarrhythmic, inhibits CYP3A4, the primary enzyme responsible for the metabolism of ticagrelor, a P2Y12 platelet inhibitor. This inhibition can lead to increased plasma concentrations of ticagrelor, potentiating its antiplatelet effect and elevating the risk of major bleeding, such as gastrointestinal or intracranial hemorrhage. Conversely, reduced ticagrelor metabolism may also affect conversion to its active metabolite, though net effect still increases overall antiplatelet activity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA vs DOCA, answered by our medical review team.
ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. DOCA is a Mineralocorticoid that works by Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA and DOCA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. The standard adult dose of DOCA is: Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA and DOCA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . DOCA is classified as Category C. FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.